The 2025-2026 COVID-19 vaccine formulation targets the SARS-CoV-2 sublineage LP.8.1, in line with FDA guidance to more closely match circulating strains1 Shipping of the LP.8.1-adapted vaccine will ...
Hosted on MSN
Pfizer Inc. (PFE)’s Updated COVID-19 Vaccine COMIRNATY LP.8.1 Gets FDA Approval, Ships Nationwide
We recently compiled a list of the 10 High Growth Pharma Stocks That Are Profitable in 2025. Pfizer Inc. stands fifth among them. Pfizer Inc. (NYSE:PFE), a global pharmaceutical leader, continues to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results